A subsidiary of Air Liquide, an Air Liquide Healthcare company, Seppic has been developing, manufacturing and marketing a wide range of innovative ingredients for cosmetic, pharmaceutical, nutraceutical and veterinary products for over 75 years.
Combining the dynamism of an international company on a human scale with the solidity of a large group, Seppic forms a team of nearly 800 talented men and women around the world who are passionate about what they do every day, serving their customers and the health, well-being and beauty of all. www.seppic.com
SEPPIC China (SSCS) is a wholly owned subsidiary of SEPPIC S.A. with more than 30 employees based in Shanghai. SEPPIC Group was acquired by Air Liquide in 1986. The company entered the China market in 1996, its business covers cosmetic ingredients and industry specialties. In 2006, SEPPIC established its manufacture plant in Qingpu, its business scope includes the development and production of adjuvants for new variety of medicines and vaccines for human and animal health and their ancillary chemical and biological intermediates; in 2015 Seppic extended its business scope to the wholesale of pharmaceutical adjuvant, nutrition additive etc.
Define the commercial plan & manage a commercial population at a specific organizational level (region, entity, country, cluster, etc.).
Main Accountabilities
Commercial Strategy: Develop and execute the commercial strategy for the Pharma, and Nutrition product lines across Great China, Korea, and Japan.
Sales Performance: Drive sales and profitability targets for the North Asia zone.
Market Development: Identify new business opportunities, key customer accounts, and market trends within North Asia.
Sales Team Leadership: Provide leadership, guidance, and performance management to the North Asia sales team.
Business development for 3 different business lines in the North Asia region and lead the relevant marketing activities.
10+ years of experience in the nutrition or pharmaceutical industry, with significant exposure to North Asia markets (China, Korea, and Japan).
Expertise in both commercial and technical/marketing functions
Experience leading cross-functional or multi-country teams, including strategic planning, coaching, and performance management.
Doctoral or Master’s degree in Pharmacy, Pharmaceutical Sciences, Life Sciences, or a related field.
Strong proficiency in English.
A world leader in gases, technologies and services for Industry and Health, Air Liquide is present in 78 countries with approximately 64,500 employees and serves more than 3.8 million customers and patients. Oxygen, nitrogen and hydrogen are essential small molecules for life, matter and energy. They embody Air Liquide’s scientific territory and have been at the core of the company’s activities since its creation in 1902.
Our Differences make our Performance
At Air Liquide, we are committed to build a diverse and inclusive workplace that embraces the diversity of our employees, our customers, patients, community stakeholders and cultures across the world.
We welcome and consider applications from all qualified applicants, regardless of their background. We strongly believe a diverse organization opens up opportunities for people to express their talent, both individually and collectively and it helps foster our ability to innovate by living our fundamentals, acting for our success and creating an engaging environment in a changing world.
Air Liquide is a world leader in gases, technologies and services for industry and healthcare. Present in 72 countries with 67,800 employees, the Group serves more than 4 million customers and patients. Oxygen, nitrogen and hydrogen are essential small molecules for life, matter and energy. They embody Air Liquide’s scientific territory and have been at the core of the Group’s activities since its creation in 1902.
Taking action today while preparing the future is at the heart of Air Liquide’s strategy. With ADVANCE, its strategic plan for 2025, Air Liquide is targeting a global performance, combining financial and extra-financial dimensions. Positioned on new markets, the Group benefits from major assets such as its business model combining resilience and strength, its ability to innovate and its technological expertise. The Group develops solutions contributing to climate and the energy transition—particularly with hydrogen—and takes action to progress in areas of healthcare, digital and high technologies.
Air Liquide’s revenue amounted to more than 27.5 billion euros in 2023. Air Liquide is listed on the Euronext Paris stock exchange (compartment A) and belongs to the CAC 40, CAC 40 ESG, EURO STOXX 50, FTSE4Good and DJSI Europe indexes.
